Biotech News

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

Foghorn Therapeutics (FHTX)Foghorn TherapeuticsPartnership

Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and

Related news

FHTXFoghorn Therapeutics2026-11-09 12:23 EST

Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-11-03 12:00 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November

ERASErasca2026-11-17 23:40 EST

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

PRLDPrelude Therapeutics2026-11-16 12:01 EST

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

CHRSCoherus BioSciences, Inc.2026-11-09 21:06 EST

Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

Foghorn Therapeutics

Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.

Recent company news

Stock data

Close
1.78 USD
Market cap
213.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States